TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer

Oncogenic KRAS mutations are encountered in more than 90% of pancreatic ductal adenocarcinomas. MEK inhibition has failed to procure any clinical benefits in mutant RAS-driven cancers including pancreatic ductal adenocarcinoma (PDAC). To identify potential resistance mechanisms underlying MEK inhibi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Discov
Main Authors: Zhao, Ben, Dierichs, Laura, Gu, Jiang-Ning, Trajkovic-Arsic, Marija, Axel Hilger, Ralf, Savvatakis, Konstantinos, Vega-Rubin-de-Celis, Silvia, Liffers, Sven-Thorsten, Peña-Llopis, Samuel, Behrens, Diana, Hahn, Stephan, Siveke, Jens T., Lueong, Smiths S.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066197/
https://ncbi.nlm.nih.gov/pubmed/32194992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41420-020-0246-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados